---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-054587"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:04:41.423263+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics supplements merger disclosures; clarifies Crescent selection, $125M PIPE

## Summary
- GlycoMimetics chose Crescent over Party A (Chinese parent) due to regulatory clearance timing risks.
- Transaction terms: $8M enterprise value for GLYC, $50M for Crescent, $125M concurrent PIPE.
- No GlycoMimetics executives will be retained or receive equity post-closing; no financial projections made.
- Term Sheet Committee formed with Mr. Junius and Mr. Pearson; dissolved after Merger Agreement execution.
- Supplemental tables update precedent IPOs, public companies, M&A, and reverse merger comparisons.

## SEC filing metadata
- accession: 0001104659-25-054587
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000110465925054587/0001104659-25-054587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000110465925054587/tm2516580d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-054587
- JSON: https://secwatch.observer/filing/0001104659-25-054587.json
- Plain text: https://secwatch.observer/filing/0001104659-25-054587.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.